Alanylation of Teichoic Acids Protects Staphylococcus aureus against Toll-like Receptor 2–Dependent Host Defense in a Mouse Tissue Cage Infection Model

Sascha A. Kristian, Xavier Lauth, Victor Nizet, Friedrich Goetz, Birgid Neumeister, Andreas Peschel, and Regine Landmann

1Microbial Genetics, University of Tübingen, and 2Department of Transfusion Medicine, University Hospitals Tübingen, Tübingen, Germany; 3Division of Pediatric Infectious Diseases, University of California, San Diego; 4Division of Infectious Diseases, Department of Research, University Hospitals Basel, Basel, Switzerland

Staphylococcus aureus is inherently resistant to cationic antimicrobial peptides because of alanylation of cell envelope teichoic acids. To test the effect of alanylated teichoic acids on virulence and host defense mediated by Toll-like receptor 2 (TLR2), wild-type (wt) S. aureus ATCC35556 (S.a.113) and its isogenic mutant expressing unalanylated teichoic acids (dlt/H11002) were compared in a tissue cage infection model that used C57BL/6 wt and TLR2−/− mice. The minimum infective doses (MID) to establish persistent infection with S.a.113 were 10³ and 10² colony-forming units (cfu) in wt and TLR2−/− mice, respectively. The corresponding MID for dlt/H11002 were 5 × 10³ and 10³ cfu in wt and TLR2−/− mice, respectively. Both mouse strains showed bacterial-load–dependent inflammation with elevations in tumor necrosis factor, macrophage inflammatory protein 2, and leukocytes, with increasing proportions of dead cells. These findings indicate that alanylated teichoic acids contribute to virulence of S. aureus, and TLR2 mediates host defense, which partly targets alanylated teichoic acids.

Received 14 November 2002; accepted 19 February 2003; electronically published 10 July 2003.


The mice used in this study were kept under specific pathogen–free conditions in the Animal House of the Department of Research, University Hospitals Basel, Switzerland, and animal experimentation guidelines were followed according to the regulations of the Swiss veterinary law.

Financial support: Swiss National Foundation (grant 31-63955.00 to R.L.); Federation of European Microbiological Societies fellowship (to S.A.K.); German Ministry of Education and Research (grant Fo-01KS9802); Interdisciplinary Center of Clinical Research Tübingen (grant to B.N.).

Reprints or correspondence: Dr. Regine Landmann, Div. of Infectious Diseases, Dept. of Research, University Hospitals Basel, Hebelstr. 20, 4031 Basel, Switzerland (regine.landmann@unibas.ch).

The Journal of Infectious Diseases 2003;188:414–23 © 2003 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2003/18803-0010$15.00

S. aureus is a leading cause of community-acquired infections of the skin, soft tissue, musculoskeletal system, respiratory tract, and endovascular system, as well as hospital-acquired bacteremias and device-associated infections [1]. As a prerequisite to establishing invasive infection, S. aureus has evolved means to circumvent host defenses [1–3]. These host defense recognition and evasion strategies of S. aureus are incompletely understood [4].

Cationic antimicrobial peptides (CAMPs), such as defensins, cathelicidins, and thrombocidins, represent an important oxygen-independent defense mechanism of the innate immune system of mammals to combat invading pathogens [5, 6]. Defensins are found in various human tissues and in neutrophils [7]; cathelicidins, including human LL-37 and mouse cathelin-related antimicrobial peptide (CRAMP) [8], are produced by keratinocytes and polymorphonuclear neutrophils (PMNs). S. aureus is inherently resistant to the antimicrobial action of defensins [3, 9] and other CAMP [3]. Esterification of cell-envelope components with amino acids most likely represents one important determinant of this resistance [5]; such modifications lead to a decrease in the net negative surface charge of the bacteria and consequently to the repulsion of CAMP [10, 11].

We have previously described an operon on the S. aureus chromosome, dltABCD, the products of which
catalyze the introduction of D-alanine into teichoic acids, staphylococcal cell envelope polymers [10]. We showed that S. aureus dlt knockout (dlt−) bacteria are highly susceptible to isolated CAMP and oxygen-independent killing mechanisms of neutrophils in vitro [12]. Both S. aureus and Listeria monocytogenes dlt− bacteria were shown to be virulence attenuated in murine sepsis models [12, 13]. However, it remained unproven whether this virulence attenuation reflected the ability of teichoic acid alanylation to protect the bacteria from leukocyte-dependent killing in vivo. To specifically address this key issue, the present study compared the virulence of S. aureus wild-type and dlt− bacteria in a mouse tissue cage infection model [14, 15]. This model was chosen because it reproduces the common characteristics of device-associated infections where S. aureus is among the most frequently isolated pathogens [16]. These infections are characterized by a low initial infecting inoculum of microorganisms, by the absence of spread beyond the vicinity of the foreign body, and by a chronic evolution until removal of the prosthesis [15]. A potential reason for the persistence of infection is biofilm formation by the bacteria. Because dlt− bacteria exhibit a dramatic reduction in their ability to colonize artificial surfaces and to form biofilm in vitro [17], additional interest to study the virulence of dlt− S. aureus in the tissue cage system is provided. We adapted the guinea pig tissue cage model [14, 18, 19] for the mouse, in which leukocyte host-defense mechanisms can be monitored and animals with targeted gene deletions are available for functional studies.

Finally, to identify precise molecular mechanisms by which teichoic acid alanylation allows S. aureus to evade host defense, we selected the host pattern recognition receptor Toll-like receptor 2 (TLR2) for study [20, 21]. When studied in vitro, TLR2 confers responsiveness of host leukocytes to heat-killed, gram-positive bacteria, including S. aureus, and to purified cell walls, peptidoglycan, lipoteichoic acid (LTA), or bacterial lipoproteins. After stimulation with these components, TLR2 mediates NF-κB translocation [22, 23] and cytokine or defensin release [24, 25]. A protective role of TLR2 has been demonstrated in murine models of S. aureus sepsis [26] and Staphylococcus pneumoniae meningitis [27]. However, it is not known which TLR2 ligand plays the major role in S. aureus–induced inflammation in vivo and whether TLR2 participates in nonoxidative antimicrobial defense mechanisms to which S. aureus with unalanlated teichoic acids are particularly sensitive. These questions were addressed by comparing the host inflammatory response to wild-type (wt) and dlt− S. aureus in C57BL/6 wt and TLR2−/− mice.

**MATERIALS AND METHODS**

**Preparation of staphylococcal strains.** S. aureus ATCC35556 (S.a.113) [28] and isogenic dltA− bacteria were used for experimental infection of the animals. The procedures used for disruption of the dltABCD operon, for plasmid construction, and for phenotypic and genotypic characterizations of dlt− have been described in detail elsewhere [10]. The staphylococcal strains were grown overnight in tryptic soy broth at 37°C without shaking, subsequently washed 3 times in large volumes of 0.9% NaCl (pH 7.4), and resuspended in saline immediately before use.

**Mice and tissue cage model.** We kept 12–16-week-old female C57BL/6 wt mice (purchased from RCC) and TLR2−/− mice, which had been backcrossed for 6 generations on a C57BL/6 background, under specific pathogen–free conditions in the Animal House of the Department of Research, University Hospitals Basel, according to the regulations of the Swiss veterinary law. Mice were anesthetized via intraperitoneal injection of 100 mg/kg ketamine (Ketalar; Warner-Lambert) and 20 mg/kg xylazine (Xylapan; Graeub), and a sterile tissue cage was implanted subcutaneously in the back [29, 30]. The cages (internal and external diameters, 8 and 10 mm, respectively; length, 30 mm; internal volume, 1.84 mL) were identical to those used in the guinea pig foreign body infection model, as described elsewhere [15], and consisted of closed polytetrafluoroethylene Teflon cylinders with 130 regularly spaced 0.2-mm holes and contained 8-sinter glass beads. After surgery, mice were treated with buprenorphine (2 mg/kg subcutaneously twice daily) for 48 h to treat postoperative pain.

Two weeks after surgery, sterility of the tissue cage was verified, and 200 μL of suspensions of S. aureus was injected percutaneously with 25-gauge needles. As reported with tissue cage infections in guinea pigs [15], mice never developed bacteremia and showed no weight change during 3 weeks of infection.

**Immunosuppression of mice with cyclophosphamide.** Mice were treated with cyclophosphamide (200 mg/kg intraperitoneally [ip]) or as control with saline (ip) every 48 h starting 2 days before experimental infection.

**Sampling of tissue cage fluid (TCF).** Mice were anesthetized by inhalation of isoflurane (Abbott); 150-μL samples of TCF were drawn by percutaneous aspiration and transferred into sterile microreaction tubes containing 15 μL of 0.9% NaCl and 1.5% EDTA (pH 7.4), to avoid clotting. In selected experiments, the pH of TCF samples was measured with pH indicator strips (Merck).

**Quantification of planktonic and adherent bacteria.** To determine the load of planktonic (free-floating) bacteria in TCF, serial dilutions of the samples were plated on Mueller-Hinton broth (MHB) agar plates. Colony-forming units were enumerated after 24-h incubation at 37°C. To quantify the number of adherent staphylococci in the Teflon cages and on the glass beads, we used a method described elsewhere [31]. In brief, mice were killed, and tissue cages were explanted under sterile conditions 6 h to 21 days after infection. Glass beads and cages...
were washed 3 times with saline and separately transferred into glass tubes containing 2–4 mL of 0.9% NaCl, EDTA (0.15%), and Triton-X (0.1%) (pH 7.4). The tubes were vortexed rigorously for 3 × 15 s, placed into an ultrasonic bath, and sonicated for 3 min at 200 W (Labsonic 2000; Bender & Hohbein). More than 95% of adherent S. aureus can be detached by this procedure [15]. After additional vortexing, appropriate volumes of serial dilutions were spread on MHB agar plates to quantify colony-forming units.

Counting of leukocytes, quantification of viable leukocytes, and identification of cell type in TCF. Leukocytes were quantified with a Coulter counter (Coulter Electronics). The percentage of viable leukocytes was assessed by trypan blue exclusion. Leukocyte differentiation in TCF was performed by Diff-Quick (Dade Behring) staining of cytopsin and examination under high-power light microscopy.

Leukocyte viability in infected TCF. TCF of uninfected and infected mice (14 days after infection) was pooled separately and centrifuged at 400 g for 10 min to remove cellular host components. Infected TCF was rendered free of residual thrombocytes and bacteria by centrifugation for 5 min at 25,000 g. Pelleted cells of uninfected TCF were then resuspended in supernatants of infected cell-free TCF. After 6-h incubation at 37°C with gentle shaking in sterile 14-mL polypropylene tubes, the viability of leukocytes was assessed as described above.

Cytokine assays. Measurement of tumor necrosis factor (TNF) and macrophage inflammatory protein (MIP)-2 in the supernatants of the samples were carried out by sandwich ELISAs that used the OptEIA mouse TNF set (PharMingen) and the Quantikine M mouse MIP-2 set (R&D Systems), respectively.

FACScan analysis. Phenotypes of TCF leukocytes were analyzed by FACS after staining with the following antibodies [32]: anti-CD11b (MAC-1; PharMingen) and anti-CD16/CD32 (FcγII/III receptor; PharMingen). Rat IgG2b (PharMingen) was used as isotype control. Fluorescein-conjugated goat anti–rat IgG (Jackson Laboratories) was used as secondary antibody.

In vitro growth of staphylococci in TCF. S.a.113 and dlt bacteria were grown and washed as described above and adjusted to ∼5 × 10⁷ cfu/mL in 100-μL pooled uninfected TCF, from which cellular components were removed by centrifugation at 400 g for 10 min and incubated at 37°C without shaking. After 24 h, 50 μL of serial dilutions was spread on MHB agar plates to quantify colony-forming units.

Susceptibility of S.a.113 and dlt to gallidermin and CRAMP. For bacterial susceptibility testing to gallidermin, TCF of wt or TLR2−/− mice containing S.a.113 or dlt was drawn 3 weeks after infection. In parallel, in vitro cultures of S.a.113 and dlt were grown in tryptic soy broth and washed as described above. Bacteria were adjusted to 1–2 × 10⁸ cfu/mL by dilution in saline. We plated 100 μL of this suspension on agar containing 0–8 μg/mL gallidermin and incubated them for 24 h at 37°C. Determination of the MIC and MBCs of CRAMP against S.a.113 or dlt bacteria was performed as described elsewhere for Streptococcus pyogenes [33].

Statistical analysis. Results of bacterial growth, TNF and MIP-2 levels, leukocyte numbers, and proportion of leukocytes alive were compared by analysis of variance for repeated measurements. P < .05 was considered to be statistically significant.

RESULTS

Staphylococcal growth in wt mice infected with S.a.113 or dlt bacteria. Our previous results in a mouse sepsis model revealed attenuated virulence of S. aureus dltA knockout bacteria (dlt−), which lack D-alanine modifications in teichoic acids, compared with wt S. aureus [12]. To characterize local host defense mechanisms to which dlt− bacteria are more susceptible than wt S. aureus (S.a.113), we adapted a guinea pig tissue cage model [14, 15, 19] to the mouse. Tissue cages implanted in wt mice were experimentally infected with S.a.113 or dlt−, and the course of disease was compared over a period of 3 weeks. Tissue cage infections in guinea pigs can be established with a low inoculum (e.g., 100–1000 cfu) for most S. aureus strains [15]. Similarly, the minimum infective dose (MID) of S.a.113 for induction of persistent infections in wt mice was found to be low (1 × 10⁷ cfu). In subsequent experiments, an inoculum of 5.3 ± 2.7 × 10³ cfu of S.a.113 was used to ensure colonization of tissue cages. S.a.113 showed in vivo growth and persistence in 10 of 10 experiments (figure 1), multiplied to 1 × 10⁸ cfu/mL within 3 days, and reached a plateau of growth at around 5 × 10⁸ cfu/mL within 6–9 days. It remained at a constant density until day 21. In contrast to S.a.113, dlt− bacteria were cleared from tissue cages in all experiments (n = 7) after delivery of a similar inoculum (7.7 ± 2.3 × 10³ cfu). In 6 of 7 experiments, no bacteria could be detected in TCF within 2 days (figure 1).
Figure 2. Tumor necrosis factor (TNF) concentration (A); macrophage inflammatory protein (MIP)-2 concentration (B); leukocyte count (C); and proportion of viable leukocytes (D) in tissue cage fluid 21 days after infection with either Staphylococcus aureus ATCC35556 (●) or S. aureus ATCC35556 dltA knockout bacteria (○) bacteria. Data are mean ± SD of at least 7 experiments in each group. * P < .05; **P < .005 (analysis of variance repeated measurements).

Quantification of planktonic bacteria does not take into account bacteria adhering to the inner surface of the implants and on the glass beads in the cages. Moreover, in the guinea pig model, staphylococci were shown to persist on the tissue cage surface, despite sterile TCF [34]; therefore, surface-adherent S.a.113 and dltA bacteria were quantified 3–21 days after infection (data not shown). Surface-adherent bacteria were never found in the presence of sterile TCF, indicating that wt mice infected with dltA bacteria were completely cured within 1–6 days. Samples from the bacterial preparations of the 2 staphylococcal strains grew equally well in MHB in vitro, indicating a similar fitness before infection (data not shown).

Because we did not obtain infection with 10³ cfu of dltA, the MID of dltA was ascertained by serially increasing the inoculum in log steps. The dltA inoculum necessary to establish a persistent infection was found to be between 5 × 10³ and 1 × 10⁴ cfu, 500–1000-fold higher than the MID of S.a.113. Infective doses of dltA bacteria showed growth behavior similar to S.a.113 (data not shown), excluding differences in bacterial replication responsible for the disparity in MID. The higher MID of dltA bacteria in the tissue cage model identifies teichoic acid alanylation as a virulence factor of S. aureus in foreign body infections.

Phenotypic and functional host responses of wt mice during infection with S.a.113 or dltA. To understand the contribution of host inflammatory responses to differences in vivo survival of S.a.113 and dltA, several parameters of host response were monitored in wt mice inoculated with the above-mentioned 5–8 × 10⁵ cfu of either bacterial strain. Leukocyte viability was evaluated, because killing of eukaryotic cells by staphylococci is known to occur [35]. Baseline leukocyte counts in the range of 1.4 × 10⁴ ± 4.6 × 10³ cells/μL were found in uninfected tissue cages and they were composed of a larger PMNs (70% ± 6%) and a smaller monocyte (24% ± 6%) fraction. These results are in agreement with those of previous reports [14, 30].

TNF release into S.a.113-infected cages was biphasic (figure 2A). A first peak with a mean value of 500 pg/mL was observed on day 1 in 5 of 10 mice, and a second peak with values between 800 and 1000 pg/mL occurred between days 7 and 10. After infection with dltA, only 3 of 7 mice had detectable TNF elevations; the average levels of TNF were much lower than after S.a.113 infection (figure 2A). Thus, TNF release correlated with the level and persistence of the bacterial load.

Leukocyte activation was further assessed by measuring expression of the cell surface receptors CD11b, representing the β-chain of the complement receptor CR3, and CD16/CD32, which is representative of FcγII/III receptors. Both receptors, which are involved in phagocytosis [36] and expressed in mononuclear and PMNs cage leukocyte populations, were measured before and 24 h after infection. The percentage of CD11b- and CD16/CD32-positive leukocytes remained constant at 90% and 96%, respectively, after infection with either S.a.113 or dltA bacteria. The mean fluorescence intensity of CD11b-positive cells increased 1.39 ± 0.28-fold and 1.42 ± 0.13-fold 24 h after infection in S.a.113- and dltA-infected cages, respective-
ly, whereas the expression of CD16/CD32 remained unaltered (0.88 ± 0.14-fold and 1.05 ± 0.17-fold, respectively). The results indicate that complement receptor upregulation was triggered independently of the virulence potential of the bacteria.

In humans, neutrophil accumulation is induced by IL-8. IL-8 has not been found in mice, but MIP-2 may serve as a neutrophil chemotactic factor with homologous function, as shown in a murine lung injury model [37]. After infection with S.a.113, the concentrations of MIP-2 in TCF increased steadily from day 1 to day 21 (figures 2B). In contrast, the dlt- mutant did not induce MIP-2, except for one mouse, which showed a modest release of MIP-2 beyond day 14 despite a sterile TCF. Elevated MIP-2 levels were followed by an influx of leukocytes into S.a.113-infected cages (figure 2C). The proportion of PMNs increased from 70% ± 6% before infection to 83% ± 1% between day 2 and day 21 after infection, corroborating a role for MIP-2 in neutrophil attraction in vivo. Cells migrated slowly into S.a.113-infected cages up to day 6 after infection but rapidly increased thereafter, culminating in a 26.7 ± 15.7-fold increase of total leukocyte numbers 21 days after infection. The leukocyte influx was completely absent (figure 2C), and the proportional changes among PMNs and monocytes did not appear (data not shown) in dlt- infected tissue cages, which is in agreement with the low MIP-2 levels observed in these mice.

Beginning at day 3 after infection with S.a.113, when bacterial colony-forming unit and leukocyte counts had reached ∼1 × 105/mL and 2 × 105/μL, respectively, the proportion of viable leukocytes steadily decline from 95% ± 3% to 48% ± 10% through day 21 after infection (figure 2D). Because of the increasing proportions of dead cells, viable leukocyte numbers increased only 13-fold during the 3 weeks of infection. In contrast, all leukocytes in dlt- infected cages remained alive. Cell death in cages infected with S.a.113 could not be attributed to an altered pH, because pH values remained constant at 7.8 ± 0.3 throughout the 21-day infection period. Furthermore, cell death was unlikely to be due to S. aureus-derived exotoxins [38], known to act rapidly [38], because uninfected cage leukocytes were not lysed during a 6-h incubation with infected cell-free TCF (data not shown).

In summary, several parameters of the host inflammatory response in the tissue cages were linked to growth and persistence of S.a.113 bacteria, absent in the dlt- infected mice.

**Role of leukocytes in host defense against dlt- bacteria.** We showed that S.a.113 and dlt- have similar growth properties in MHB medium in vitro. In contrast, we found the MID for dlt- bacteria is much higher than that for S.a.113. We therefore tested whether dlt- bacteria were more susceptible to soluble factors and/or to leukocytes present in TCF. S.a.113 and dlt- grew similarly when cultured in vitro in TCF of uninfected mice after removing cellular components by centrifugation (data not shown). This finding indicates that the clearing of dlt- bacteria in wt mice was due to cell-associated host factors absent in uninfected, cell-free TCF.

To prove an essential role for leukocytes in clearance of dlt- bacteria, wt mice were rendered leukopenic by means of the immunosuppressive drug cyclophosphamide. Cyclophosphamide injections reduced leukocyte numbers in uninjected cages by 75% to 3.5 × 105 ± 1.6 × 105 leukocytes/μL. As shown in figure 3, dlt- bacteria were no longer cleared in leukopenic wt mice and grew at a similar rate as S.a.113. These results strongly suggest that leukocytes mediate the host defense against S. aureus in tissue cage infections.

**Role of TLR2 in host defense against dlt- bacteria.** TLR2-/- mice were shown to be highly susceptible to infection by S. aureus [26] and S. pneumoniae [27]. We tested whether TLR2 participates in the immune defense against S.a.113 and dlt- bacteria during tissue cage infection by comparing the course of disease in wt and TLR2-/- mice. First, the MIDs for S.a.113 and dlt- were determined in TLR2-/- mice. The average MIDs of 102 cfu (S.a.113) and 103 cfu (dlt-) in TLR2-/- mice (figure 4A) were 10-fold (P < .05) and 500–1000-fold lower, respectively, than those observed in wt mice (table 1). Thus, TLR2 is involved in murine host defense against S. aureus in tissue cage infections, and its role is prominent in the rapid clearance of dlt- bacteria by wt mice. However, even in TLR2-/- mice, dlt- bacteria had a 10-fold higher MID than S.a.113 (table 1, figure 4A). This reflects a higher susceptibility of the mutant bacteria to additional host defense mechanisms not related to TLR2.

**Course of disease in TLR2-/- mice.** To assess the evolution of infection in the absence of TLR2-mediated defense mechanisms, TLR2-/- mice were infected with the same inocula of S.a.113 and dlt- as used in the wt mice challenges. As shown in figure 4B, S.a.113 grew in TLR2-/- mice and reached a plateau of growth 3 days after infection. The bacterial growth rate was faster than that observed in wt mice, where colony-

---

Figure 3. Effect of in vivo leukocyte depletion on bacterial growth in tissue cages. Growth of Staphylococcus aureus ATCC35566 (S.a.113) (black symbols) and S. aureus ATCC35566 dltA knockout bacteria (dlt-) (white symbols) bacteria in wild-type mice treated with saline (circles) or with cyclophosphamide (triangles). Results are colony-forming unit values of 1 representative experiment.
forming unit counts were maximal only after 6–9 days (figures 4 and 1). The \( dlt^- \) bacteria, which were cleared in \( wt \) mice (figure 1), proliferated in TLR2-deficient hosts (\( n = 7; \) figure 4B), thus identifying a role of TLR2 in murine immune defense against bacteria expressing unalanylated teichoic acids. Nevertheless, the \( dlt^- \) bacteria showed significantly delayed growth, compared with \( wt \) bacteria (\( P < .01; \) figure 4B), reaching maximum levels on day 14—that is, 11 days later than \( S.a.113 \).

TCF from untreated TLR2\(^{−/−} \) mice showed \( 1.1 \times 10^7 \pm 5.2 \times 10^3 \) leukocytes/\( \mu L \) with 74% \( ± \) 9% PMNs and 17% \( ± \) 7% monocytes, which was similar to the values found in \( wt \) mice. Furthermore, bacterial replication in the tissue cage elicited an inflammatory response in the TLR2\(^{−/−} \) host similar to that observed in \( wt \) mice. This response was characterized by increasing concentrations of TNF (figure 5A) and MIP-2 (figure 5B), by leukocyte influx (figure 5C), and by a decrease in leukocyte viability (figure 5D). However, for all parameters measured, infection with \( S.a.113 \) induced a stronger response than did infection with the \( dlt^- \) mutant. The \( S.a.113 \)-induced TNF response was biphasic, with a high peak after 1 day and a plateau from day 7 onward. In contrast, \( dlt^- \) infection induced TNF only in the late phase, and average values were lower than in \( S.a.113 \)-infected mice (figure 5A). MIP-2 was also induced faster and significantly more strongly in \( S.a.113 \)-infected mice (figure 4B).

The delayed, weaker TNF and MIP-2 responses are most likely the consequence of the slower growth of the mutant bacteria in TLR2\(^{−/−} \) mice. Infection in TLR2\(^{−/−} \) mice was followed by leukocyte influx. Total leukocyte counts in \( S.a.113 \)- and \( dlt^- \)-infected cages increased 11.5 \( ± \) 6.4-fold and 12.8 \( ± \) 5.5-fold 21 days after infection, respectively (figure 5C). However, the maximum leukocyte concentration in TLR2\(^{−/−} \) mice was lower (2.8 \( \times \) 10\(^5 \) leukocytes/\( \mu L \)) than that in \( wt \) mice (5.9 \( \times \) 10\(^5 \) leukocytes/\( \mu L \); figure 2C). Leukocyte influx was also accompanied by a decreasing fraction of living cells (figure 4E). In \( S.a.113 \)-infected cages, viability started to decline after day 2, whereas, in \( dlt^- \)-infected cages, it started to decrease after day 7.

**Susceptibility of \( S.a.113 \) and \( dlt^- \) to antibacterial peptides.** CAMPs are deployed by the innate immune system in response to \( S. aureus \) infections. In a previous study, human PMNs exhibited a stronger bactericidal activity in vitro toward \( dlt^- \) bacteria than on \( wt \) \( S.a.113 \) [12]. This difference paralleled the higher susceptibility of \( dlt^- \) to CAMP [12]. It is known that TLRs participate in the induction of CAMP [25]. In tissue cages, the majority of the cells are PMNs, which are known to release a CAMP of the cathelicidin family, CRAMP [33]. Therefore, we compared the susceptibility of \( S.a.113 \) and \( dlt^- \) bacteria to CRAMP in vitro. The MICs and MBCs of CRAMP were 4-fold lower for \( dlt^- \), compared with \( S.a.113 \) (figure 6A). To confirm a differential sensitivity of \( S.a.113 \) and \( dlt^- \) bacteria to CAMP in vivo, the susceptibility of \( S.a.113 \) and \( dlt^- \) to gallidermin, a CAMP of bacterial origin, was assessed after harvesting the bacteria from cages 3 weeks after infection. The gallidermin concentration required to kill 50% of the applied staphylococci was \( \sim 1 \mu g/mL \) for \( S.a.113 \) and \(< 0.3 \mu g/mL \) for \( dlt^- \) bacteria (figure 6B). This result supports a hypothesis that neutrophil-
derived CAMP such as CRAMP could be responsible for the killing of dlt\(^{-}\) bacteria in tissue cages in wt mice.

**DISCUSSION**

In the present study, we investigated the role of the dltABCD-mediated resistance against cationic antimicrobial host components in *S. aureus* virulence, and we investigated whether this immune escape mechanism protects against TLR2-dependent host defense. In a mouse tissue cage infection model, we found that alanylated teichoic acids protect against host defense—in large part, those pathways mediated by TLR2.

*S. aureus* teichoic acids mediate resistance against host defense by several mechanisms. Esterification of teichoic acids with amino acids decreases the net negative surface charge of the staphylococcal cells, thereby conferring resistance to CAMPs [10, 11] and other nonoxidative antimicrobial effector mechanisms, including phospholipase A\(_2\) [39]. Indeed, dlt\(^{-}\) bacteria with unalanylated teichoic acids are more susceptible to CAMP [10] and phospholipase A\(_2\) [39]. Alanlation of teichoic acids also affects the capacity of the bacteria to adhere on glass and plastic surfaces; accordingly, dlt\(^{-}\) bacteria exhibit reduced adhesion to artificial surfaces [17].

In this study, we investigated how alanylation of teichoic acids affect *S. aureus* survival during a local infection in vivo. Furthermore, teichoic acids were studied as potential targets of the pattern recognition receptor TLR2, prompted by the fact that purified LTA activates cells through TLR2 [22]. In contrast to LTA, cell-wall teichoic acid has not yet been examined for its interaction with TLR2. *S. aureus* cell-wall teichoic acid differs from LTA in its lack of a lipid anchor and in the nature of its repeating sugar units. Yet, we hypothesize that TLR2 is engaged by both teichoic acid and LTA and that the TLR2-mediated effector mechanisms are influenced by the charge (i.e., alanylation) of the 2 components. TLR2 has 2 important functions: it transmits a proinflammatory signal in response to LTA, peptidoglycan, or lipoprotein stimulation [22, 23, 40]; and it exerts a protective role for the host during infection with *S. aureus* and other gram-positive bacteria. The mechanism of this protective role remains unknown.

We found that dlt\(^{-}\) was less virulent than wt *S.a.113*, as determined by the 500–1000-fold higher MID of the mutant in wt mice. This finding indicates that the susceptibility to oxygen-independent antimicrobial host mechanisms facilitates bacterial clearing. Indeed, dlt\(^{-}\) were more sensitive to CRAMP in vitro and gallidermin ex vivo. Future studies that use CRAMP\(^{-/-}\) mice, which lack the mouse neutrophil cathelicidin CRAMP [33], will address whether murine cathelicidins are responsible for clearing of dlt\(^{-}\) in the tissue cage model. An increased sensitivity to phospholipase A\(_2\) which we described recently for dlt\(^{-}\) bacteria [39], could not explain clearing of the dlt\(^{-}\) mutant in our model, because C57/BL6 mice are deficient in phospholipase A\(_2\) [41]. It is also unlikely that dlt\(^{-}\) bacteria were more sensitive to oxidative killing because they were cleared equally in vivo in the presence and absence of the free radical scavenger \(\alpha\)-phenyl-ter-butylnitrone (data not shown).

---

**Figure 5.** Course of disease in Toll-like receptor 2–deficient mice. **A**, Tumor necrosis factor (TNF) concentration; **B**, macrophage inflammatory protein (MIP)–2 concentration; **C**, leukocyte counts; **D**, leukocyte viability in tissue cages during 21 days after infection with *Staphylococcus aureus* ATCC35556 (S.a.113) (●) or *S. aureus* ATTC35556 dltA knockout bacteria (dlt\(^{-}\)) (○) bacteria. Data are mean ± SD of at least 7 least experiments in each group. *P < .05; **P < .005 (analysis of variance repeated measurements).
an agent known to effectively decrease oxidative injury in group B streptococcal meningitis [42]. Finally, clearing of dtl- bacteria is apparently not related to a reduced colonization on glass surfaces in vivo, because no differences were found between S.a.113 and dtl- in adhesion.

Because dtl- are more susceptible to CAMP, it was interesting to investigate whether innate receptors, which are known to contribute to CAMP release, participate in their elimination. TLR2 could play such a role, although so far only β-defensin was shown to be induced via TLR2 [25] and this induction was measured after stimulation with bacterial lipoprotein. Up-regulation of cathelicidin expression after infection with live bacteria occurs by an unknown mechanism. Future studies will address the question whether TLR2 modulates cathelicidin release. We found the MID of dtl- was 1000-fold lower in TLR2-/- mice than in wt mice. Although 10^9 to 10^6 cfu were required in wt mice, only 10^3 cfu caused an infection in TLR2-/- mice. This means that TLR2 recognition and/or effector mechanisms are important in the control of dtl- bacteria. Of interest, dtl- remained less virulent than S.a.113 in TLR2-/- mice, indicating that TLR2-independent mechanisms also contribute to bacterial clearance.

Whether TLR2 participates directly in bacterial clearance is not clear. It is unlikely that phagocytosis is influenced by TLR2, because zymosan uptake in macrophages was shown to be TLR2 independent [43]. It is possible that engagement of TLR2 leads to bacterial killing through an increased generation of CAMP, via reactive oxygen species or via release of chemokines that recruit additional leukocytes to the site of infection. Furthermore, TLR2 activation might induce killing via a nitric oxide–dependent mechanism, as shown during infection with Mycobacterium tuberculosis [44].

Our tissue cage model also demonstrates that TLR2 contributes moderately to efficient killing of S.a.113. The MID of S.a.113 was 10-fold lower in TLR2-/- mice than in wt mice. Early S.a.113 growth was faster in the absence of TLR2. Comparison of S.a.113 and dtl- in the 2 mouse strains implies that alanylated teichoic acids protect S. aureus from TLR2-mediated defense. Three mechanisms not mutually exclusive can be envisaged. First, dtl- bacteria may bind to host cell TLR2 more strongly than S.a.113. Second, they may bind to other phagocytic receptors, which leads to efficient clearing only in the presence of TLR2. Third, both S.a.113 and dtl- may activate leukocytes to an equivalent degree, but the mutant may be killed faster and better because of its increased susceptibility to CAMP. It remains to be determined which of these mechanisms is TLR2 dependent.

Our results deserve 2 further comments. In tissue cage infection, the inflammatory response was very strong. However, the onset of the inflammatory response was delayed and strictly correlated with bacterial number. Release of MIP-2 and TNF showed a biphasic pattern. After 24 h of infection, small amounts of both mediators were detected, and these levels were not associated with cessation of bacterial growth. Of interest, this early initial peak was present in TLR2-/- mice and therefore is mediated by TLR2-independent mechanisms. We also found an increased expression of CR3 during the early stage of infection in both mouse strains, again independent of TLR2. The inflammation response in this model was then characterized by a second phase with release of extremely large amounts of MIP-2 and TNF, high leukocyte numbers, and massive leukocyte cell death. This delayed and apparently insufficient response appears when the bacteria reach high numbers and does not affect bacterial clearance. This phenomenon is likely a by-product of the closed infection model and might resemble the pathophysiology of implant-associated infection in humans.

A final comment concerns the association of S. aureus virulence with the expression of alanylated teichoic acids. In the tissue cage model, bacteria have a growth advantage as a consequence of the delayed inflammatory response. Nevertheless, S. aureus is immediately cleared when it expresses unalanylated teichoic acids that render them highly susceptible to the action of CAMP. Future strategies that target enzymes encoded by the dltABCD operon may be of benefit in therapy of S. aureus infection.
Acknowledgments

We thank Zarko Rajaic and Fabrizia Ferracin, for excellent technical support; Terence O’Reilly (Novartis Pharma, Basel, Switzerland), for providing tissue cages; William J. Rieflin (Tularik, South San Francisco, CA), for Toll-like receptor 2–deficient mice; Richard Gallo (Veterans Affairs San Diego Health Care System, San Diego), for providing cathelin-related antimicrobial peptide; Gennaro De Libero (University Hospital, Basel, Switzerland), for critically reading the manuscript; Werner Zimmerli (Kantonsspital Liestal, Liestal, Switzerland), for helpful discussions.

References

IIA phospholipase A₂ against *Staphylococcus aureus*. J Biol Chem 2002; 277:47636–44.